Tanezumab Terminated Phase 3 Trials for Osteoarthritis (OA) Treatment

Indications	Status	Purpose	Phase
DBCOND0056529 (Osteoarthritis (OA))	Terminated	Treatment	3

clinicaltrials.gov Identifier	Title	Drugs
NCT01127893	Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis	Tanezumab (DB12335)
NCT00985621	Tanezumab In Osteoarthritis Of The Hip Or Knee	Oxycodone (DB00497) Tanezumab (DB12335)
NCT00960804	Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients	Tanezumab (DB12335)
NCT00863772	Tanezumab and Nerve Function In Arthritis Patients	Tanezumab (DB12335)
NCT00864097	Analgesic Efficacy And Safety of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip	Diclofenac (DB00586) Tanezumab (DB12335)
NCT00809783	Extension Study Of Tanezumab In Osteoarthritis	Tanezumab (DB12335)